Vaccines and antibodies in the prevention and treatment of sepsis.
Antibodies to various core glycolipid antigens have been shown to correlate with survival from Gram-negative sepsis. Recent preclinical data also support efficacy of the anti-core glycolipid antibodies in the treatment of sepsis. Failure of some of the previous clinical trials with anti-core glycolipid antibody was probably due to inadequate levels of antibody in those preparations. Future clinical trials must ensure that sufficient amounts of anti-core glycolipid antibodies are present in the circulation of patients with sepsis.
Bhattacharjee
A K
AK
Department of Bacterial Diseases, Walter Reed Army Institute of Research, Washington, DC, USA.
Cross
A S
AS
D000818:Animals; D000907:Antibodies, Bacterial / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000276:immunology* / Q000627:therapeutic use; D004731:Endotoxins / Q000737:chemistry / Q000276:immunology; D006017:Glycolipids / Q000276:immunology; D016905:Gram-Negative Bacterial Infections / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D019081:O Antigens / Q000737:chemistry / Q000276:immunology; D018805:Sepsis / Q000517:prevention & control / Q000628:therapy*; D014611:Vaccination
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D001428:Bacterial Vaccines; D004731:Endotoxins; D006017:Glycolipids; D019081:O Antigens